These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 29029063)

  • 1. Impact of Pneumococcal Vaccination on Pneumonia Hospitalizations and Related Costs in Ontario: A Population-Based Ecological Study.
    Luca DL; Kwong JC; Chu A; Sander B; O'Reilly R; McGeer AJ; Bloom DE
    Clin Infect Dis; 2018 Feb; 66(4):541-547. PubMed ID: 29029063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands.
    van Deursen AMM; Schurink-Van't Klooster TM; Man WH; van de Kassteele J; van Gageldonk-Lafeber AB; Bruijning-Verhagen PCJL; de Melker HE; Sanders EAM; Knol MJ
    Vaccine; 2017 Dec; 35(51):7107-7113. PubMed ID: 29146381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis.
    Andrade AL; Afonso ET; Minamisava R; Bierrenbach AL; Cristo EB; Morais-Neto OL; Policena GM; Domingues CMAS; Toscano CM
    PLoS One; 2017; 12(9):e0184204. PubMed ID: 28880953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico.
    Wasserman M; Palacios MG; Grajales AG; Baez/Revueltas FB; Wilson M; McDade C; Farkouh R
    Hum Vaccin Immunother; 2019; 15(3):560-569. PubMed ID: 30156978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.
    Berglund A; Ekelund M; Fletcher MA; Nyman L
    PLoS One; 2014; 9(11):e112211. PubMed ID: 25379659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children.
    Nair H; Watts AT; Williams LJ; Omer SB; Simpson CR; Willocks LJ; Cameron JC; Campbell H
    BMC Infect Dis; 2016 Aug; 16():390. PubMed ID: 27506837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
    Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
    BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
    Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I; Krajden S; Ostrowska K; Richardson D; Richardson S; Sarabia A; Silverman M; Simor AE; Tyrrell G; McGeer A;
    Vaccine; 2013 Dec; 31(49):5863-71. PubMed ID: 24099873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Have changing pneumococcal vaccination programmes impacted disease in Ontario?
    Lim GH; Wormsbecker AE; McGeer A; Pillai DR; Gubbay JB; Rudnick W; Low DE; Green K; Crowcroft NS; Deeks SL
    Vaccine; 2013 May; 31(24):2680-5. PubMed ID: 23597716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumonia in Elderly Australians: Reduction in Presumptive Pneumococcal Hospitalizations but No Change in All-Cause Pneumonia Hospitalizations Following 7-Valent Pneumococcal Conjugate Vaccination.
    Menzies RI; Jardine A; McIntyre PB
    Clin Infect Dis; 2015 Sep; 61(6):927-33. PubMed ID: 26066319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a Pediatric Referral Hospital in Uruguay.
    Pírez MC; Algorta G; Chamorro F; Romero C; Varela A; Cedres A; Giachetto G; Montano A
    Pediatr Infect Dis J; 2014 Jul; 33(7):753-9. PubMed ID: 24492286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses.
    Suarez V; Michel F; Toscano CM; Bierrenbach AL; Gonzales M; Alencar AP; Ruiz Matus C; Andrus JK; de Oliveira LH
    Vaccine; 2016 Sep; 34(39):4738-4743. PubMed ID: 27521230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children.
    Mezones-Holguín E; Bolaños-Díaz R; Fiestas V; Sanabria C; Gutiérrez-Aguado A; Fiestas F; Suárez VJ; Rodriguez-Morales AJ; Hernández AV
    J Infect Dev Ctries; 2014 Dec; 8(12):1552-62. PubMed ID: 25500653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
    Strutton DR; Farkouh RA; Earnshaw SR; Hwang S; Theidel U; Kontodimas S; Klok R; Papanicolaou S
    J Infect; 2012 Jan; 64(1):54-67. PubMed ID: 22085813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.
    Haasis MA; Ceria JA; Kulpeng W; Teerawattananon Y; Alejandria M
    PLoS One; 2015; 10(7):e0131156. PubMed ID: 26131961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.